The Remarkable Track Record of COVID-19 Vaccines

Three vaccines originating in the U.S. and abroad are highly successful in averting or diminishing COVID-19 with acceptable safety profiles.

Several vaccines against SARS-CoV-2 have received emergency approval. Now, two groups describe the effectiveness and safety of two vaccines (approved and widely used in the U.S.) and the efficacy of a third (in use in many other parts of the world).

In a postapproval prospective cohort study of the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines, the 3975 participants from six U.S. states included demographically representative healthcare workers, first responders, and frontline workers with possible exposure to SARS-CoV-2. Weekly RT-PCR testing was performed on nasal swabs between December 14, 2020, and April 10, 2021. SARS-CoV-2 was detected in 5 fully vaccinated (2 doses; at least 14 days postvaccination), 11 partly vaccinated…

Reviewing Author

Stephen G. Baum, MD

Disclosures

Consultant/Advisory BoardClinical Infectious Diseases

RoyaltiesUpToDate

Editorial BoardsMedical Letter

Stephen G. Baum, MD

Disclosures

Consultant/Advisory BoardClinical Infectious Diseases

RoyaltiesUpToDate

Editorial BoardsMedical Letter

The Remarkable Track Record of COVID-19 Vaccines

Topics

Reviewing Author